Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Guinea declares mpox outbreak over after 42 days without cases

    November 21, 2026

    WFP seeks $12.1 billion to feed 91 million people in 2027

    November 21, 2026

    South Korea’s exports pass $1 trillion for the first time

    November 21, 2026
    Facebook X (Twitter) Instagram
    UAE IndependentUAE Independent
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • More
      • Sports
      • Technology
      • Travel
    UAE IndependentUAE Independent
    Home » Cambridge Isotope Laboratories, Inc. Expands 13C Production Capacity With North Star Project
    ACCESS Newswire

    Cambridge Isotope Laboratories, Inc. Expands 13C Production Capacity With North Star Project

    September 5, 2024
    Facebook Twitter Pinterest LinkedIn Tumblr Email

    TEWKSBURY, MA / ACCESSWIRE / September 5, 2024 / Cambridge Isotope Laboratories, Inc. (CIL), the global leader in 13Cand 13C urea production, is excited to announce the startup of its North Star project, significantly increasing the company’s production capabilities.

    CIS Aerial
    CIS Aerial
    CIS Aerial

    The North Star project commenced in mid-2020 as the world’s largest 13C production cascade. After the complex build of phase one finished in March 2024, CIL began to introduce naturally abundant product into the front end of the distillation cascade. With each stage of the cascade, the predicted enrichment has exceeded expectations, and the overall performance has been exceptional. The first highly enriched 13C finished product will be captured in October of 2024. CIL will build more front-end systems to bring final production of the cascade to world scale capacities by April 2025.

    “This is CIL’s fourth 13C production system since 1990. With each system, our team of talented engineers have incorporated their 30-plus years of design, operation, and construction experience into the next system. Our North Star cascade is certainly proving that knowledge and experience pays impactful dividends for CIL and our customers,” said Cliff Caldwell, CEO of CIL.

    “CIL’s talented organic chemists incorporate our 13C product into a myriad of labelled organic compounds with significant importance in environmental testing, biopharmaceutical research, and medical diagnostics. One critical product is 13C Urea used in the detection of H-pylori infections in humans. H-pylori is widespread throughout the world and can lead to stomach ulcers and stomach cancer. 13C urea provides a low-cost detection method to allow for treatment and elimination of H-pylori. The North Star project assures CIL’s commitment to meeting the needs of 13C urea and accommodate future growth in other critical applications,” states Mike Steiger, Vice President of Engineering and Project Execution.

    For years, CIL has been the go-to expert in cryogenic distillation, solidifying its position as the world’s top producer of 13C isotopes. CIL’s customers can be assured they have the reliable capacity of 13C to meet enable the commercialization of their research.

    About Cambridge Isotope Laboratories, Inc.

    CIL is the world’s largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL subsidiary ABX, located in Dresden, Germany, is active in the development and commercialization of radio isotopic-labeled compounds for the diagnosis and treatment of cancers. CIL is an operating business owned by Otsuka Pharmaceutical. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France. For more information on CIL, visit isotope.com.

    Contact Information

    Crissy Krisko
    crissyk@isotope.com
    1.978.269.1930

    SOURCE: Cambridge Isotope Laboratories, Inc.

    View the original press release on newswire.com.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    American Businessman Mark Eric Williams Vindicated in Six-Year, US$150 Million-Plus Litigation Brought by Kuwaiti State Entities

    November 20, 2026

    Freezz Italia Awarded ESA Contract for IRIS(2) Low-LEO Pre-Operational and De-Risk Activities

    November 17, 2026

    Securitas Healthcare Introduces a New Era of RTLS Built for the Future of Healthcare Operations

    November 10, 2026
    Latest News

    Guinea declares mpox outbreak over after 42 days without cases

    Health November 21, 2026

    Guinea has declared an end to its mpox outbreak after two full incubation periods passed with no new active cases or chains of transmission. The government made the announcement on Thursday, November 19. Health Minister Khaite Sall said in an

    WFP seeks $12.1 billion to feed 91 million people in 2027

    November 21, 2026

    South Korea’s exports pass $1 trillion for the first time

    November 21, 2026

    Air Arabia Egypt launches Cairo to Al Ain flights now

    November 20, 2026

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    PM Modi meets Prince and Princess of Wales in New Delhi

    November 19, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    DXB handles 50.4 million passengers in first nine months

    November 18, 2026
    © 2026 UAE Independent | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.